159 related articles for article (PubMed ID: 18442035)
1. Towards small-molecule CXCR3 ligands with clinical potential.
Wijtmans M; Verzijl D; Leurs R; de Esch IJ; Smit MJ
ChemMedChem; 2008 Jun; 3(6):861-72. PubMed ID: 18442035
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and structure-activity relationships of 3H-quinazolin-4-ones and 3H-pyrido[2,3-d]pyrimidin-4-ones as CXCR3 receptor antagonists.
Storelli S; Verzijl D; Al-Badie J; Elders N; Bosch L; Timmerman H; Smit MJ; De Esch IJ; Leurs R
Arch Pharm (Weinheim); 2007 Jun; 340(6):281-91. PubMed ID: 17562560
[TBL] [Abstract][Full Text] [Related]
3. Discovery of small molecule benzimidazole antagonists of the chemokine receptor CXCR3.
Hayes ME; Wallace GA; Grongsaard P; Bischoff A; George DM; Miao W; McPherson MJ; Stoffel RH; Green DW; Roth GP
Bioorg Med Chem Lett; 2008 Mar; 18(5):1573-6. PubMed ID: 18242988
[TBL] [Abstract][Full Text] [Related]
4. Special ergolines are highly selective, potent antagonists of the chemokine receptor CXCR3: discovery, characterization and preliminary SAR of a promising lead.
Thoma G; Baenteli R; Lewis I; Wagner T; Oberer L; Blum W; Glickman F; Streiff MB; Zerwes HG
Bioorg Med Chem Lett; 2009 Nov; 19(21):6185-8. PubMed ID: 19783143
[TBL] [Abstract][Full Text] [Related]
5. Small Molecule CXCR3 Antagonists.
Andrews SP; Cox RJ
J Med Chem; 2016 Apr; 59(7):2894-917. PubMed ID: 26535614
[TBL] [Abstract][Full Text] [Related]
6. Chemical subtleties in small-molecule modulation of peptide receptor function: the case of CXCR3 biaryl-type ligands.
Wijtmans M; Scholten DJ; Roumen L; Canals M; Custers H; Glas M; Vreeker MC; de Kanter FJ; de Graaf C; Smit MJ; de Esch IJ; Leurs R
J Med Chem; 2012 Dec; 55(23):10572-83. PubMed ID: 23150943
[TBL] [Abstract][Full Text] [Related]
7. CXCR3 antagonists: quaternary ammonium salts equipped with biphenyl- and polycycloaliphatic-anchors.
Wijtmans M; Verzijl D; Bergmans S; Lai M; Bosch L; Smit MJ; de Esch IJ; Leurs R
Bioorg Med Chem; 2011 Jun; 19(11):3384-93. PubMed ID: 21570852
[TBL] [Abstract][Full Text] [Related]
8. Identification of CXCR3 receptor agonists in combinatorial small-molecule libraries.
Stroke IL; Cole AG; Simhadri S; Brescia MR; Desai M; Zhang JJ; Merritt JR; Appell KC; Henderson I; Webb ML
Biochem Biophys Res Commun; 2006 Oct; 349(1):221-8. PubMed ID: 16930533
[TBL] [Abstract][Full Text] [Related]
9. Designing small molecule CXCR3 antagonists.
Pease JE
Expert Opin Drug Discov; 2017 Feb; 12(2):159-168. PubMed ID: 28010133
[TBL] [Abstract][Full Text] [Related]
10. Special ergolines efficiently inhibit the chemokine receptor CXCR3 in blood.
Thoma G; Baenteli R; Lewis I; Jones D; Kovarik J; Streiff MB; Zerwes HG
Bioorg Med Chem Lett; 2011 Aug; 21(16):4745-9. PubMed ID: 21764306
[TBL] [Abstract][Full Text] [Related]
11. II. SAR studies of pyridyl-piperazinyl-piperidine derivatives as CXCR3 chemokine antagonists.
Shao Y; Anilkumar GN; Carroll CD; Dong G; Hall JW; Hobbs DW; Jiang Y; Jenh CH; Kim SH; Kozlowski JA; McGuinness BF; Rosenblum SB; Schulman I; Shih NY; Shu Y; Wong MK; Yu W; Zawacki LG; Zeng Q
Bioorg Med Chem Lett; 2011 Mar; 21(5):1527-31. PubMed ID: 21277198
[TBL] [Abstract][Full Text] [Related]
12. Development of CXCR3 antagonists. Part 2: Identification of 2-amino(4-piperidinyl)azoles as potent CXCR3 antagonists.
Watson RJ; Allen DR; Birch HL; Chapman GA; Hannah DR; Knight RL; Meissner JW; Owen DA; Thomas EJ
Bioorg Med Chem Lett; 2007 Dec; 17(24):6806-10. PubMed ID: 17964154
[TBL] [Abstract][Full Text] [Related]
13. Noncompetitive antagonism and inverse agonism as mechanism of action of nonpeptidergic antagonists at primate and rodent CXCR3 chemokine receptors.
Verzijl D; Storelli S; Scholten DJ; Bosch L; Reinhart TA; Streblow DN; Tensen CP; Fitzsimons CP; Zaman GJ; Pease JE; de Esch IJ; Smit MJ; Leurs R
J Pharmacol Exp Ther; 2008 May; 325(2):544-55. PubMed ID: 18270317
[TBL] [Abstract][Full Text] [Related]
14. Suppression of experimental autoimmune myasthenia gravis by inhibiting the signaling between IFN-gamma inducible protein 10 (IP-10) and its receptor CXCR3.
Feferman T; Aricha R; Mizrachi K; Geron E; Alon R; Souroujon MC; Fuchs S
J Neuroimmunol; 2009 Apr; 209(1-2):87-95. PubMed ID: 19232748
[TBL] [Abstract][Full Text] [Related]
15. Design and optimization of imidazole derivatives as potent CXCR3 antagonists.
Du X; Chen X; Mihalic JT; Deignan J; Duquette J; Li AR; Lemon B; Ma J; Miao S; Ebsworth K; Sullivan TJ; Tonn G; Collins TL; Medina JC
Bioorg Med Chem Lett; 2008 Jan; 18(2):608-13. PubMed ID: 18063364
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and structure-activity relationship of benzetimide derivatives as human CXCR3 antagonists.
Bongartz JP; Buntinx M; Coesemans E; Hermans B; Lommen GV; Wauwe JV
Bioorg Med Chem Lett; 2008 Nov; 18(21):5819-23. PubMed ID: 18922694
[TBL] [Abstract][Full Text] [Related]
17. Modelling of the membrane receptor CXCR3 and its complexes with CXCL9, CXCL10 and CXCL11 chemokines: putative target for new drug design.
Trotta T; Costantini S; Colonna G
Mol Immunol; 2009 Dec; 47(2-3):332-9. PubMed ID: 19800124
[TBL] [Abstract][Full Text] [Related]
18. Emerging new chemokine CXCR3 antagonists and their potential clinical and therapeutic applications.
Kapoor S
Hepatology; 2009 Apr; 49(4):1400-1. PubMed ID: 19330874
[No Abstract] [Full Text] [Related]
19. A novel QSAR model for predicting the inhibition of CXCR3 receptor by 4-N-aryl-[1,4] diazepane ureas.
Afantitis A; Melagraki G; Sarimveis H; Igglessi-Markopoulou O; Kollias G
Eur J Med Chem; 2009 Feb; 44(2):877-84. PubMed ID: 18619714
[TBL] [Abstract][Full Text] [Related]
20. Photoswitching the Efficacy of a Small-Molecule Ligand for a Peptidergic GPCR: from Antagonism to Agonism.
Gómez-Santacana X; de Munnik SM; Vijayachandran P; Da Costa Pereira D; Bebelman JPM; de Esch IJP; Vischer HF; Wijtmans M; Leurs R
Angew Chem Int Ed Engl; 2018 Sep; 57(36):11608-11612. PubMed ID: 29926530
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
